The biotechnology company receives a notice of allowance for its U.S. patent application on the OptiMAL® platform, a critical part of its antibody engineering services.
The biotechnology company is hosting an online investor presentation to discuss its recent trading update.
The biotechnology company has issued new shares to its non-executive directors as part of their compensation.
The healthcare company's CEO has purchased additional shares, increasing his direct holding in the business.
The healthcare company has announced a change in shareholding, with no further details provided.
The biotechnology company reported a 71% increase in revenues for the financial year, driven by growth in the Diagnostics and Veterinary sectors. The firm also secured non-dilutive funding through grants and a successful equity raise.
The contract research organization has been awarded a grant to develop a novel antibody therapy, providing non-dilutive funding for the project.
The healthcare company has announced changes to its major shareholders.
The healthcare company has announced a change in its major shareholder, with Unicorn Asset Management Limited increasing its stake in the business.
The biotechnology company has announced changes to its major shareholders.